Intensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors
Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumors (NETs) while still effectively delivering treatment throughout the whole body. This hybrid approach safely delivered over three times more radiation directly to liver metastases, resulting in encouraging…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
